The Committee, composed of CEOs of fourteen leading multinational companies from Canada, Europe, India, Israel, Japan and the United States was established by the International Generic and Biosimilar medicines Association (IGBA) to provide a forum for industry leaders to discuss broad, strategic issues, and to engage and position the industry on a range of critical policy issues.

“This is the first time that the generic and biosimilar medicines industry’s company leadership has united in a structured framework, enabling a collective voice in the global pharmaceutical space”, said Vivian Frittelli, IGBA Chair.

Suzette Kox, IGBA Secretary General added “This industry has clearly lived up to the challenges posed by the pandemic. In many instances, there is now clear recognition that the generic and biosimilar medicines industry is the answer for affordable and sustainable solutions in such situations and beyond. It is vital that generic, biosimilar and value-added medicines now become central to global healthcare policies”.

This vision of the role of our industry in the global healthcare system is shared by Markus Sieger, CEO Polpharma Group. “To help people live a healthy life in a healthy world, I will strongly contribute to this Committee in areas such as patient compliance and other aspects of healthcare with digital and other innovative solutions” – commented Markus.

See all members of the CEO Advisory Committee: 

Members of the IGBA CEO Advisory Committee 2022 >>>

The International Generic and Biosimilar Medicines Association (IGBA) was founded in March 1997 as an international network of generic medicines associations. IGBA strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. The association maintains constant dialogue with other national, regional and international bodies.